MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93,796,527 | -25.3% | 642,266 | +18.1% | 0.01% | -28.6% |
| Q2 2023 | $125,608,329 | -0.3% | 543,759 | +4.6% | 0.01% | 0.0% |
| Q1 2023 | $125,930,140 | -82.8% | 519,814 | -79.4% | 0.01% | -68.2% |
| Q4 2022 | $732,006,436 | +1065.2% | 2,521,986 | +160.9% | 0.02% | +450.0% |
| Q3 2022 | $62,822,000 | +6.3% | 966,641 | +17.1% | 0.00% | 0.0% |
| Q2 2022 | $59,075,000 | -21.4% | 825,307 | +7.8% | 0.00% | 0.0% |
| Q1 2022 | $75,148,000 | +48.1% | 765,879 | +27.9% | 0.00% | +100.0% |
| Q4 2021 | $50,738,000 | -16.2% | 598,748 | -21.1% | 0.00% | -33.3% |
| Q3 2021 | $60,530,000 | -0.2% | 758,615 | +21.9% | 0.00% | 0.0% |
| Q2 2021 | $60,634,000 | -11.5% | 622,462 | +6.3% | 0.00% | -25.0% |
| Q1 2021 | $68,515,000 | -4.2% | 585,750 | -9.0% | 0.00% | 0.0% |
| Q4 2020 | $71,528,000 | +39.7% | 643,415 | +49.2% | 0.00% | +33.3% |
| Q3 2020 | $51,202,000 | -25.3% | 431,244 | -28.7% | 0.00% | -40.0% |
| Q2 2020 | $68,543,000 | +115.3% | 605,235 | +26.9% | 0.01% | +66.7% |
| Q1 2020 | $31,830,000 | -23.8% | 476,780 | +4.0% | 0.00% | 0.0% |
| Q4 2019 | $41,763,000 | -3.6% | 458,378 | -8.7% | 0.00% | 0.0% |
| Q3 2019 | $43,305,000 | -33.1% | 502,265 | -18.7% | 0.00% | -40.0% |
| Q2 2019 | $64,746,000 | -8.7% | 617,746 | +9.1% | 0.01% | -16.7% |
| Q1 2019 | $70,943,000 | +4.8% | 566,362 | -5.7% | 0.01% | 0.0% |
| Q4 2018 | $67,680,000 | -26.2% | 600,427 | +40.2% | 0.01% | -14.3% |
| Q3 2018 | $91,704,000 | -4.3% | 428,269 | +25.0% | 0.01% | -12.5% |
| Q2 2018 | $95,800,000 | +78.2% | 342,506 | -25.6% | 0.01% | +60.0% |
| Q1 2018 | $53,766,000 | +739.8% | 460,371 | +560.0% | 0.01% | +400.0% |
| Q4 2017 | $6,402,000 | +218.2% | 69,753 | +55.6% | 0.00% | – |
| Q3 2017 | $2,012,000 | +273.3% | 44,820 | +35.1% | 0.00% | – |
| Q2 2017 | $539,000 | +2466.7% | 33,170 | -58.3% | 0.00% | – |
| Q2 2016 | $21,000 | – | 79,573 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |